Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Zogenix Inc. ZGNX

Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes Fintepla, dose fenfluramine for the treatment of Dravet syndrome, and MT-1621 for a rare, life-threatening mitochondrial depletion disease, thymidine kinase 2 deficiency (TK2d). It operates as a single operating segment engaged in the research, development, and commercialization of pharmaceutical products.


NDAQ:ZGNX - Post by User

Bullboard Posts
Post by traderguy5000on Apr 30, 2016 3:33pm
226 Views
Post# 24829190

Cash

CashLiabilities they are not going to pay? That's way over my head. But how is it even possible for them to have $1.9M at the end of calendar 2016? Sean told me their base burn is $70k US per month, or about $90k CAN. So they would burn $1.080M in a year. Starting with $2.148M at the end of calendar year 2015, would leave them with $1.068M at the end of calendar 2016. It would actually be less, as their actual burn is greater than their base burn. I'm certainly no expert on their finances, but I don't see how they could end calendar 2016 with $1.9M. They state in the MD&A they anticipate a cash balance of $300k at the end of 2016, and I believe them. Their cash flows support that number.

Could you provide more detail on your higher estimate?

Liquidity and Financial Position

Expected use of funds for fiscal 2016 includes:

Budget from January 1, 2016 to December 31, 2016 ($ millions) (1)

Cash inflow

 

Cash balance at December 31, 2015

2.1

Cash receivable from Exxon

0.1

Total cash inflow

2.2

   

Cash outflow

 

Exploration expenses and capital expenditures

0.5

General and corporate expenses

1.4

Total cash outflow

1.9

Expected cash balance

0.3 


Bullboard Posts